Nektar Therapeutics (NKTR) Misses Q1 EPS by 182c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $39.17 -1.85%
EPS Growth %: -213.5%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -213.5%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($1.82). Revenue for the quarter came in at $10.9 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deere & Co. (DE), Others Fall on Chatter of FTC Probe
- Deutsche Bank's top picks in mining as copper market faces potential squeeze
- Evercore ISI Reiterates Outperform Rating on Arista Networks (ANET)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
